Abstract
The antiarrhythmic effect of flecainide acetate (FCN), a newly developed class I antiarrhythmic drug, was evaluated on epinephrine (E)-halothane induced arrhythmias in dogs. The arrhythmogenic dose of E (ADE) under 1%of halothane was significantly increased from 0.71±0.08 to 1.08±0.11 and 1.84±0.23 μ·kg−1·min−1 by the administration of 2 and 4 mg·kg−1 of FCN, respectively. The arrhythmias induced by ADE in the absence of FCN were stopped by 1.78 ±0.29 mg·kg−1 of FeN in bolus injections. These results suggest that FCN can be used for the treatment of arrhythmias that E contributes to under halothane anesthesia.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Borchard U, Boisten M: Effect of flecainide on action potentials and alternating current-induced arrhythmias in mammalian myocardium. J Cardiovasc Pharmacol 4:205–212, 1982
Schulze JJ, Kneps J: Effects of flecainide on contractile force and electrophysiological parameters in cardiac muscle. Arznei Forsch 32 II:1025–1029, 1982
Ikeda N, Davis L, Hauswirth 0, Singh BN: Flecainide: electrophysiologic profile in isolated cardiac muscle of an antiarrhythmic with differential effects in ventricular muscle and Purkinje fibers. Circulation 66 (Suppl 11):379, 1982
Kvan DC, Banitt EH, Schmid JR: Antiarrhythmic and electrophysiologic actions of flecainide in animal models. Am J Cardiol 53:22B-25B, 1984
Somani P: Antiarrhythmic effects of flecainide. Clin Pharmacol Therap 27:464–470, 1980
Abitbol H, Califano JE, Abate C, Bellis P, Castellanos H: Use of flecainide acetate in the treatment of premature ventricular contractions. Am Heart J 102:227–230, 1983
Hodges M, Salerno DM, Granrud G, the Flecainide-Quinidine research group: Flecainide versus quinidine: results of multicenter trial. Am J Cardiol 53:66B-71B, 1984
Anderson JL: Experience with electrophysiologically guided therapy of ventricular tachycardia with flecainide: summary of long-term follow-up. Am J Cardiel 53:79B-86B, 1984
Camm AJ, Hellestrand KJ, Nathan AW, Bexton RS: Clinical usefulness of fiecainide acetate in the treatment of paroxysmal supraventricular arrhythmias. Drugs 29 (suppl 4):7–13, 1985
Esters III NAM, Garan H, Ruskin IN: Electrophysiological properties of flecainide acetate. Am J Cardiol 53:26B-29B, 1984
Katz RL, Epstein RA: The interaction of anesthetic agents and adrenergic drugs to produce cardiac arrhythmias. Anesthesiology 29:763–784, 1968
Legrand V, Vandormael M, Collignon P, Kulbertus HE: Haemodynarnic effects of a new antiarrhythmic agent, flecainide (R818), in coronary heart disease. Am J Cardiel 51:422–426, 1983
Serry PW, Vanhaleweyk G, van dan Brand M, Verdouw P, Lubsen J, Hugenholtz PG: The haemodynamic effect of intravenous flecainide acetate in patients with coronary artery disease. Brit J Clin Pharmacol 16:51–59, 1983
Josephson MA, Ikeda N, Singh BN: Effects of flecainide on ventricular function: Clinical and experimental correlations. Am J Cardiol 53:95B-100B, 1984
Author information
Authors and Affiliations
About this article
Cite this article
Iwatsuki, N., Takahashi, M., Satoh, S. et al. The antiarrhythmic effect of flecainide on halothane-epinephrine induced arrhythmias in dogs. J Anesth 4, 303–308 (1990). https://doi.org/10.1007/s0054000040303
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s0054000040303